Results 181 to 190 of about 38,022 (310)

Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes. [PDF]

Biomedicines
Cozma D, Văcărescu C, Stoicescu C.
europepmc   +1 more source

Impact of diabetes mellitus and grip strength on postoperative outcomes in older patients undergoing cancer surgery: A single‐center retrospective cohort study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction Diabetes mellitus (DM) increases postoperative risks and may worsen physical function through muscle loss. Patients undergoing malignancies surgery are aging, and age‐related declines in physical function, particularly sarcopenia, also adversely affects outcomes.
Taku Fujimoto, Kie Uchikawa, Hiroshi Akasaka, Yukiko Yasunobe, Shino Yoshida, Yuri Onishi, Tomohiro Minami, Yuki Asada, Masaaki Isaka, Ken Sugimoto, Kotaro Yamashita, Norikatsu Miyoshi, Takehiro Noda, Hirofumi Akita, Mamoru Uemura, Yukinori Kurokawa, Hidetoshi Eguchi, Yuichiro Doki, Hiroshi Koriyama, Koichi Yamamoto   +19 more
wiley   +1 more source

Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy. [PDF]

Amino Acids
Fajkić A, Lam YW, Belančić A.
europepmc   +1 more source

GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes. [PDF]

J Am Geriatr Soc
Chen JC, Fang YW, Liu YF, Chen MT, Tsai MH.   +4 more
europepmc   +1 more source

Effect of switching from intermittently scanned continuous glucose monitoring to FreeStyle Libre 2 with real‐time continuous glucose monitoring and alert functionality

Journal of Diabetes Investigation, EarlyView.
Transitioning from FSL to FSL2 with rtCGM function improved sensor usage and glycemic control, particularly in patients with Type 1 diabetes. The duration required for improvement in continuous glucose monitoring‐related parameters varied by diabetes type, with early improvements observed in Type 1 diabetes and gradual improvements in Type 2 diabetes ...
Keiji Sugai, Junko Sasaki, Gakuyuki Tomizawa, Ryo Suzuki   +3 more
wiley   +1 more source

Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial

Diabetes, Obesity and Metabolism, EarlyView.
Luxcia Kugathasan, Michael A. Tsoukas, Massimo Nardone, Vikas S. Sridhar, Marcel H. A. Muskiet, David Z. I. Cherney, Ahmad Haidar, Melissa‐Rosina Pasqua   +7 more
wiley   +1 more source

Efficacy of probiotics (Bifidobacterium bifidum G9‐1) in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation: An exploratory, multicenter, open‐label, single‐arm study (BIRDIE study)

Journal of Diabetes Investigation, EarlyView.
Bifidobacterium bifidum G9‐1 improved stool form, defecation frequency, and Quality of Life in patients with type 2 diabetes mellitus and chronic kidney disease complicated by constipation. ABSTRACT Introduction Although constipation is a major complication of type 2 diabetes mellitus and chronic kidney disease, evidence for its treatment in these ...
Fuki Ikeda, Junko Sato, Hidenori Yoshii, Masahiro Sugawara, Hiroaki Satoh, Yukiko Sugawara, Hirotsugu Uzawa, Daisuke Sugimoto, Reina Muto, Yuya Nishida, Hirotaka Watada   +10 more
wiley   +1 more source

Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland. [PDF]

Healthcare (Basel)
Nowak K, Dziewierz A, Sojda A, Zabojszcz M, Szarpak Ł, Dardzinska N, Jaskulska P, Siudak Z.   +7 more
europepmc   +1 more source

Retrospective comparison of the clinical effects of oral semaglutide and SGLT2 inhibitors treatment in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This retrospective study compared oral semaglutide and SGLT2 inhibitors in patients with type 2 diabetes over 6 months. Both treatments significantly reduced HbA1c, body weight, and fat mass. Although the reduction in fat mass was comparable, changes in skeletal muscle mass tended to be less favorable with SGLT2 inhibitors than with oral semaglutide ...
Yasuhiro Omori, Ryota Usui, Yuji Yamazaki, Hitoshi Kuwata, Yoshiyuki Hamamoto, Yuichiro Yamada, Yutaka Seino   +6 more
wiley   +1 more source

Real-World Use of GLP-1 Receptor Agonist Liraglutide in Adolescents with Obesity: A First Longitudinal Single-Center Analysis from Switzerland. [PDF]

Children (Basel)
Noordam C, Eiholzer U, Katschnig C, Stasinaki A, Dubinski I.   +4 more
europepmc   +1 more source